Zobrazeno 1 - 10
of 199
pro vyhledávání: '"H, Suttmann"'
Autor:
K, Miller, P, Albers, R, Eichenauer, G, Geiges, M-O, Grimm, F, König, G, Mickisch, D, Pfister, C, Schwentner, H, Suttmann, S, Zastrow
Publikováno v:
Der Urologe. Ausg. A. 55(9)
Therapies currently available in Germany for metastatic castration-resistant prostate cancer (mCRPC) include docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and radium-223, all of which offer a potential survival benefit that adds up in the
Publikováno v:
Der Onkologe. 13:1101-1108
Zwei aktuelle Metaanalysen konnten einen signifikanten Einfluss auf das Uberleben von Patienten nach radikaler Zystektomie sowohl fur adjuvante als auch neoadjuvante Cisplatin-basierte Chemotherapieregime zeigen. Beide Metaanalysen, die die zurzeit b
Publikováno v:
Der Urologe. 45:629-636
Immuntherapeutische Ansatze zur Bekampfung solider Tumorerkrankungen haben bislang zumeist nur experimentellen Charakter. Lediglich die intravesikale Immuntherapie mit Bacillus-Calmette-Guerin (BCG) des oberflachlichen Harnblasenkarzinoms stellt die
Autor:
K, Miller, P, Hammerer, R, Eichenauer, G, Geiges, J, Lehmann, G, Rodemer, C, Ruessel, W, Rulf, H, Suttmann, J M, Wolff
Publikováno v:
Aktuelle Urologie. 44(4)
Androgen deprivation therapy is an integral part of the treatment of advanced and progressive prostate cancer. Various prospective randomised trials have investigated whether or not temporary suspension of androgen deprivation might delay the emergen
Publikováno v:
Der Urologe. Ausg. A. 51(12)
In Germany misteltoe extract is one of the most commonly used complementary therapeutic strategies in oncology. There are anthroposophical as well as phytotherapeutic concepts to explain the potential mechanism of action; however, the oncological and
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Der Urologe. Ausg. A. 48(2)
The optimal extent of lymphadenectomy performed during radical cystectomy for transitional cell carcinoma of the bladder is currently under intensive debate. Extending the limits of lymphadenectomy has been hypothesized to add further diagnostic and
Autor:
J, Lehmann, H, Suttmann, P, Albers, B, Volkmer, J E, Gschwend, G, Fechner, M, Spahn, A, Heidenreich, A, Odenthal, C, Seif, N, Nürnberg, C, Wülfing, C, Greb, T, Kälble, M-O, Grimm, C F, Fieseler, S, Krege, M, Retz, H, Schulte-Baukloh, M, Gerber, M, Hack, J, Kamradt, M, Stöckle
Publikováno v:
Der Urologe. Ausg. A. 48(2)
Recent publications suggest that a subgroup of patients can benefit from surgical removal of transitional cell carcinoma (TCC) metastases in addition to systemic chemotherapy. We report the combined experience and outcome of patients undergoing resec
Publikováno v:
Der Urologe. Ausg. A. 47(2)
Over the last two decades, nephron-sparing surgery has gained more and more importance. Initially it was done for imperative indications to preserve the remaining function of solitary kidneys. Today, because of favourable oncological results, electiv
Publikováno v:
Der Urologe. Ausg. A. 46(10)
Two recent meta-analyses demonstrated a significant influence of adjuvant as well as neoadjuvant cisplatin-based chemotherapy regimens on survival of patients undergoing radical cystectomy for bladder cancer. Therefore, the introductory question can